Phase 4
Completed N=31
Lipids of the Human Tear Film and Their Effect on Tear Stability
Source: ClinicalTrials.gov NCT00803452 ↗Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcomePrimary: Global Response to Therapy — 16; 41 eyes — p=.001
◆ Published Evidence
Highly cited
176citations · ~11 / year
Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations.
Summary
This prospective, randomized, comparative clinical trial evaluates the effect of either oral doxycycline, oral essential fatty acid, or topical azithromycin to modify the secretions of the meibomian gland in subjects with meibomian gland dysfunction and/or dry eye disease.
Linked Publications (3)
-
Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations.
-
Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study.
-
Human meibum lipid conformation and thermodynamic changes with meibomian-gland dysfunction.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Global Response to Therapy |
16; 41 | .001 sig |
Eligibility Criteria
Inclusion Criteria
- Meibomian gland dysfunction
Exclusion Criteria
- Lid margin scarring; herpetic blepharitis
Data sourced from ClinicalTrials.gov (NCT00803452) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.